publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
patient
acut
exacerb
chronic
bronchiti
treat
antibiot
advantag
use
fluoroquinolon
patholog
chang
chronic
bronchiti
cb
produc
airflow
obstruct
reduc
effect
mucocilliari
drainag
system
lead
bacteri
colonis
bronchial
secret
presenc
bacteria
induc
inflammatori
respons
mediat
leukocyt
direct
relationship
degre
impair
mucocilliari
drainag
system
densiti
bacteria
mucu
number
leukocyt
sputum
purul
sputum
good
marker
high
bacteri
load
eventu
number
leukocyt
high
normal
activ
could
decreas
effect
drainag
system
increas
bronchial
obstruct
probabl
damag
lung
parenchymawhenev
densiti
bacteria
bronchial
lumen
cfu
ml
high
probabl
degre
inflammatori
respons
lead
viciou
cycl
turn
tend
sustain
process
situat
aris
clinic
cours
acut
exacerb
cb
independ
aetiolog
provid
episod
suffici
sever
prolong
fluoroquinolon
third
fourth
gener
bactericid
microorgan
usual
relat
acut
exacerb
cb
diffus
bronchial
mucu
adequ
use
short
treatment
reduc
bacteri
load
higher
proport
achiev
blactam
macrolid
antibiot
given
oral
although
clinic
cure
rate
similar
obtain
antibiot
time
exacerb
could
increas
chronic
bronchiti
cb
clinic
defin
presenc
product
cough
last
three
consecut
month
two
consecut
year
patient
clinic
diagnosi
cb
suffer
sever
chang
respiratori
tract
airway
chang
mostli
locat
bronchiol
includ
differ
degre
chronic
inflammatori
infiltr
mucosa
mainli
due
macrophag
lymphocyt
reduct
number
ciliat
cell
well
ciliari
length
hypertrophi
bronchial
submucosa
gland
well
caliciform
cell
turn
lead
excess
mucu
product
progress
fibrosi
airway
wall
includ
loss
elast
fibr
keep
bronchiol
open
chang
due
primari
secondari
immunolog
respons
longterm
inhal
smoke
harm
gase
biolog
dust
develop
countri
tobacco
smoke
respons
case
cb
howev
heavi
smoker
develop
cb
nearli
diseas
progress
fact
suggest
particular
baselin
genet
individu
suscept
necessari
shown
presenc
sever
polymorph
gene
codifi
inflammatori
mediat
proteas
antiproteas
develop
autoimmun
respons
perhap
presenc
chronic
viral
infect
infect
due
chlamydophila
pneumonia
structur
function
chang
develop
patient
cb
lead
nonrevers
slowli
progress
obstruct
bronchial
lumen
well
reduct
effect
mucocilliari
drainag
system
microorgan
eventu
enter
respiratori
airway
via
inhal
air
follow
microaspir
pharyng
content
impact
mucu
airway
trap
mucin
macromolecul
next
mucocilliari
drainag
system
carri
microorgan
oropharynx
process
bacteri
clearanc
peripher
airway
last
h
period
presenc
lactoferrin
lysozym
secretori
leukoproteinas
inhibitor
among
antimicrobi
compound
bronchial
secret
hamper
growth
microorgan
respiratori
airway
kept
steril
whenev
two
factor
ie
speed
drainag
bacteri
growth
inhibitori
capac
greater
total
amount
microorgan
enter
respiratori
tract
take
account
rate
reproduct
microorgan
mycoplasma
pneumonia
c
pneumonia
bordetella
pertussi
specif
mechan
allow
stick
bronchial
mucosa
epitheli
layer
therefor
avoid
move
oropharynx
eventu
produc
infecti
tracheobronch
healthi
peopl
reduct
effect
mucocilliari
drainag
system
relat
cb
pulmonari
patholog
chang
allow
bacteri
colonis
bronchial
lumen
bacteri
popul
densiti
directli
relat
degre
impair
bronchial
drainag
system
turn
correl
well
sever
airway
obstruct
initi
stage
cb
among
patient
fev
valu
predict
cultur
bronchial
secret
appar
steril
bacteri
viabl
count
cfu
ml
drainag
system
obstruct
worsen
probabl
colonis
increas
bacteri
densiti
also
increas
declin
effect
drainag
system
last
long
enough
lead
follow
day
new
balanc
bronchial
mucu
tend
harbour
greater
degre
bacteri
load
microorgan
kept
low
even
undetect
number
bronchial
mucu
patient
stabl
cb
confirm
fact
sputum
cultur
becom
neg
follow
appropri
antibiot
treatment
bacteri
phenotyp
reappear
clinic
relaps
diseas
develop
presenc
bacteria
surfac
otherwis
normal
steril
mucosa
trigger
activ
leukocyt
second
defens
mechan
innat
immun
tolllik
receptor
express
epithelium
bronchial
mucosa
well
macrophag
recognis
specif
bacteri
compon
activ
nuclear
kb
factor
start
product
cytokin
interleukin
chemokyn
growth
factor
intercellular
adher
molecul
selectin
icam
arachidon
acid
metabolit
leukotrien
direct
consequ
includ
develop
inflammatori
respons
polymorphonuclear
leukocyt
pmn
adher
pulmonari
blood
vessel
endothelium
migrat
bronchial
lumen
degre
inflamm
well
number
pmn
cell
sputum
cb
patient
directli
relat
bacteri
densiti
bronchial
secret
also
note
good
relationship
exist
gross
appear
sputum
greenish
color
purul
sputum
due
presenc
leukocyt
myeloperoxidas
pmn
count
grossli
purul
sputum
like
harbour
high
bacteri
load
case
antibacteri
mechan
neutrophil
includ
among
other
product
reactiv
oxygen
speci
ro
eg
superoxid
anion
hydroxyl
radic
well
hydrogen
peroxid
sever
serin
proteas
elastas
proteinas
cathepsin
g
matrix
metalloproteinas
cystein
proteinas
cathepsin
k
l
proteas
activ
rapidli
neutralis
specif
inhibitor
eg
elfin
secretori
leukoproteas
inhibitor
tissu
inhibitor
matrix
metalloproteinas
timp
proteinas
cistatin
ro
inactiv
antiproteas
free
proteas
ro
effect
includ
enhanc
inflammatori
respons
mucu
product
likelihood
lung
damag
ensu
worsen
airway
obstruct
fev
reduct
final
lead
emphysema
anim
model
probabl
also
human
bacteri
densiti
low
leukocyt
count
also
low
give
mucoid
appear
sputum
sever
antiproteas
easili
neutralis
total
amount
proteas
produc
leukocyt
hand
bacteri
count
high
purul
appear
sputum
relat
higher
concentr
proteas
make
ineffect
antiproteas
neutralis
activ
final
result
like
worsen
respiratori
tract
obstruct
togeth
impair
mucocilliari
drainag
system
turn
maintain
even
increas
growth
bacteria
summari
given
threshold
bacteri
load
bronchial
secret
degre
inflammatori
respons
may
enter
viciou
cycl
vc
sustain
process
fig
summaris
event
data
patient
cb
indic
sever
inflammatori
respons
may
chang
function
particular
bacteria
prevail
bronchial
mucu
pseudomona
aeruginosa
produc
higher
degre
inflamm
produc
haemophilu
influenza
turn
higher
due
moraxella
catarrhali
haemophilu
parainfluenza
overal
critic
densiti
bacteria
bronchial
mucu
lead
vc
lie
around
cfu
ml
chronic
product
purul
sputum
link
impair
fev
well
higher
risk
sever
chronic
obstruct
pulmonari
diseas
copd
exacerb
requir
hospitalis
acut
exacerb
cb
associ
presenc
higher
bacteri
load
bronchial
mucu
clinic
evolut
patient
cb
characteris
regular
appear
worsen
episod
bronchial
inflamm
due
bacteri
viral
infect
case
remain
episod
due
environment
factor
air
pollut
dust
temperatur
lack
complianc
baselin
treatment
develop
cardiac
disrythmia
among
infrequ
encount
caus
viral
infect
mainli
due
rhinoviru
follow
coronaviru
respiratori
synciti
viru
rsv
influenza
parainfluenza
viru
adenoviru
recent
demonstr
human
metapneumoviru
play
role
acut
exacerb
cb
case
bacteri
infect
due
acquisit
new
h
influenza
strain
less
frequent
catarrhali
strain
probabl
show
higher
virul
compar
strain
present
bronchial
mucu
surfac
antigen
protein
gene
h
influenza
mutat
allow
microorgan
escap
immun
respons
properti
perhap
could
explain
exacerb
sever
studi
demonstr
serolog
evid
acut
c
pneumonia
infect
cb
exacerb
observ
confirm
author
independ
underli
caus
acut
exacerb
cb
carri
risk
impair
mucocilliari
drainag
system
increas
bacteri
popul
densiti
turn
trigger
greater
inflammatori
respons
even
initi
trigger
acut
exacerb
episod
bacteri
infect
enhanc
risk
next
day
bacteria
particip
activ
process
determin
final
evolut
densiti
threshold
level
gener
vc
reach
likelihood
seri
event
depend
two
main
factor
sever
durat
trigger
caus
baselin
situat
cb
patient
greater
bacteri
charg
baselin
greater
risk
given
phenomenon
independ
aetiolog
contribut
bronchial
inflamm
lead
exacerb
due
even
higher
bacteri
load
fig
higher
bacteri
load
stabl
clinic
condit
often
seen
among
cb
patient
histori
repeat
acut
exacerb
moder
sever
degre
bronchial
obstruct
rate
acut
exacerb
higher
patient
advanc
stage
cb
measur
degre
bronchial
obstruct
signific
proport
patient
acut
exacerb
cb
recoveri
incomplet
bacteri
speci
often
found
cultur
bronchial
secret
cb
patient
sputum
sampl
taken
either
clinic
stabl
phase
acut
exacerb
decreas
order
nontyp
h
influenza
streptococcu
pneumonia
catarrhali
patient
sever
airflow
impair
fev
enter
gramneg
bacilli
enter
gnb
escherichia
coli
klebsiella
enterobact
well
nonfer
gnb
mostli
p
aeruginosa
also
isol
bronchial
secret
bacteria
found
less
frequent
includ
staphylococcu
aureu
h
parainfluenza
presenc
gnb
due
great
extent
higher
rate
antibiot
usag
treatment
acut
exacerb
among
patient
moder
sever
cb
risk
factor
pharyng
colonis
gnb
eg
advanc
age
sever
underli
condit
diabet
mellitu
chronic
renal
failur
cirrhosi
liver
cancer
chronic
debilit
diseas
also
risk
factor
pharyng
colonis
among
patient
cb
bronchial
secret
sampl
cb
patient
give
growth
polymicrobi
flora
often
differ
h
influenza
strain
coexist
patient
even
differ
antibiot
suscept
presenc
pneumococci
reduc
likelihood
colonis
infect
h
influenza
associ
h
influenza
pneumococci
found
less
frequent
expect
take
account
high
frequenc
independ
isol
singl
pathogen
follow
evid
present
clinic
decis
use
antibiot
treatment
patient
acut
exacerb
cb
must
reli
find
bacteri
infect
primari
caus
exacerb
situat
turn
often
difficult
identifi
rather
acknowledg
situat
bacteri
presenc
like
factor
contribut
fig
sequenc
event
lead
start
vc
patient
cb
patient
cb
start
point
bacteri
load
left
axi
therefor
degre
purul
sputum
right
axi
low
repres
point
due
mild
impair
mucocilliari
drainag
system
caus
acut
exacerb
present
drainag
system
hamper
patient
statu
move
b
point
correspond
level
bacteri
load
purul
sputum
point
close
threshold
level
cfu
ml
bacteri
densiti
viciou
cycl
start
see
text
adequ
antibiot
treatment
reduc
degre
bacteri
load
move
patient
point
exacerb
irrespect
initi
caus
trigger
current
episod
benefit
antibiot
treatment
acut
exacerb
cb
matter
debat
well
known
publish
studi
antibiot
compar
placebo
show
statist
signific
differ
reason
could
explain
result
includ
low
number
patient
studi
lack
stratif
patient
accord
sever
score
acut
exacerb
well
select
antibiot
antibiot
dosag
may
deem
optim
accord
current
knowledg
pharmacodynam
penetr
blactam
antibiot
bronchial
secret
due
passiv
diffus
free
fraction
unbound
protein
bestcas
scenario
blactam
antibiot
level
bronchial
secret
c
maximum
plasma
peak
level
antibiot
cephaclor
cefuroxim
erythromycin
administ
oral
usual
recommend
dose
last
long
enough
bronchial
mucu
level
mic
h
influenza
develop
optim
antibacteri
efficaci
metaanalysi
includ
nine
randomis
placebocontrol
clinic
trial
conduct
show
slight
benefit
favour
antibiot
placebo
clinic
efficaci
peakflow
improv
consid
endpoint
studi
conduct
anthonisen
et
al
patient
stratifi
accord
sever
acut
exacerb
show
benefit
antibiot
treatment
measur
clinic
improv
well
fev
valu
speed
improv
particularli
signific
acut
exacerb
episod
characteris
presenc
dyspnoea
increas
volum
sputum
purul
appear
sputum
benefit
lower
albeit
still
signific
two
three
criteria
met
similar
result
obtain
anoth
studi
patient
also
classifi
three
group
accord
sever
bronchial
obstruct
measur
fev
valu
although
antibiot
treatment
efficaci
better
placebo
group
benefit
higher
group
patient
higher
degre
function
impair
import
valuabl
data
regard
antibiot
treatment
patient
acut
exacerb
cb
provid
doubl
blind
randomis
clinic
trial
ofloxacin
compar
placebo
studi
includ
patient
sever
acut
exacerb
cb
requir
mechan
ventil
patient
ofloxacin
group
less
often
need
antibiot
treatment
total
durat
mechan
ventil
length
hospit
stay
well
mortal
rate
significantli
lower
ofloxacin
placebo
group
use
antibiot
patient
acut
exacerb
cb
decid
follow
assess
clinic
present
acut
episod
baselin
statu
patient
procedur
allow
identif
two
main
group
cb
patient
like
benefit
antibiot
treatment
patient
sever
acut
exacerb
requir
hospit
admiss
patient
purul
sputum
product
good
marker
presenc
high
bacteri
count
patient
degre
sever
acut
exacerb
advancedstag
cb
determin
sever
airflow
obstruct
fev
prior
histori
three
acut
exacerb
last
year
prior
episod
sever
acut
exacerb
requir
hospit
admiss
studi
conduct
anthonisen
et
al
suggest
episod
acut
exacerb
cb
least
two
follow
three
criteria
present
call
type
ii
exacerb
benefit
antibiot
treatment
criteria
includ
increas
short
breath
increas
sputum
volum
product
purul
sputum
rel
weight
presenc
purul
sputum
like
higher
presenc
two
criteria
probabl
justifi
use
antibiot
patient
acut
exacerb
clinic
characteris
increas
dyspnoea
increas
volum
sputum
product
analys
independ
nevertheless
recent
studi
show
patient
acut
exacerb
cb
start
antibiot
treatment
earlier
significantli
faster
recoveri
rate
also
patient
commonli
consult
primari
physician
acut
exacerb
appear
higher
likelihood
admit
hospit
sever
episod
fluoroquinolon
fq
class
antibiot
offer
sever
advantag
special
interest
clinician
use
empir
treatment
respiratori
tract
infect
bactericid
effect
rapid
depend
concentr
achiev
primari
site
infect
properti
give
basi
use
shortterm
day
treatment
patient
acut
exacerb
cb
extend
halfliv
fq
allow
use
singl
daili
dose
antimicrobi
spectrum
activ
socal
third
gener
fq
levofloxacin
gatifloxacin
gemifloxacin
fourth
gener
fq
moxifloxacin
garenoxacin
includ
import
microorgan
involv
acut
exacerb
cb
eg
h
influenza
catarrhali
pneumonia
togeth
microorgan
also
identifi
occasion
eg
c
pneumonia
pneumonia
addit
fq
activ
high
percentag
enterobacteriacea
ciprofloxacin
well
levofloxacin
activ
high
number
p
aeruginosa
strain
although
activ
levofloxacin
p
aeruginosa
lower
ciprofloxacin
invivo
efficaci
quinolon
similar
pharmacokinet
properti
levofloxacin
favour
allow
antibiot
achiev
area
concentrationtim
curv
h
steadi
state
divid
mic
auc
mic
ratio
equival
ciprofloxacin
antibacteri
spectrum
activ
fq
acquir
paramount
import
whenev
high
antibiot
resist
rate
record
sever
area
world
h
influenza
notabl
catarrhali
strain
blactamas
produc
case
respect
also
pneumonia
strain
show
macrolid
penicillinresist
nearli
case
diffus
fq
antibiot
lung
tissu
suffici
level
achiev
higher
plasma
level
alveolar
fluid
insid
alveolar
macrophag
lesser
extent
bronchial
mucosa
secondgener
fq
level
bronchial
secret
reach
valu
plasma
level
data
avail
third
fourth
gener
fq
pharmacodynam
paramet
best
predict
clinic
efficaci
fq
auc
mic
complet
elimin
pneumonia
achiev
auc
mic
valu
infect
due
p
aeruginosa
enter
gnb
auc
mic
valu
need
turn
requir
use
ciprofloxacin
dose
mg
everi
h
levofloxacin
dose
mg
everi
h
optim
auc
mic
valu
h
influenza
catarrhali
unknown
probabl
close
valu
regist
pneumococci
potenti
exist
high
bacteri
load
acut
exacerb
cb
import
risk
factor
select
resist
mutant
mutat
occur
spontan
region
genet
determin
quinolon
resist
qrdr
parc
gyra
singl
mutat
usual
produc
slight
increas
mic
depend
intrins
fq
activ
antibiot
could
still
effect
howev
second
mutat
appear
certainli
lead
bacteri
crossresist
fq
antibiot
suscept
test
perform
minor
chang
resist
level
must
identifi
might
point
exist
first
step
mutat
use
fq
avoid
order
prevent
select
strain
develop
second
step
mutat
impli
crossresist
reason
prudent
avoid
long
durat
fq
treatment
patient
cb
well
avoid
use
fq
patient
cb
treat
recent
fq
h
influenza
pneumonia
bacteri
popul
present
bronchial
secret
cb
patient
often
heterogen
clone
differ
antibiot
suscept
easili
coexist
fq
resist
clone
perhap
aris
prior
fq
treatment
could
remain
hidden
vast
sensit
popul
rapidli
select
prevail
day
new
fq
antibiot
treatment
cours
start
sinc
begin
widespread
use
fq
antibiot
treatment
respiratori
tract
infect
sever
isol
case
togeth
small
outbreak
fqresist
pneumonia
respiratori
tract
infect
report
notabl
cb
patient
previous
treat
fq
resist
isol
relationship
clone
dissemin
spars
date
epidemiolog
studi
conduct
recent
unit
state
canada
sever
european
union
countri
show
resist
rate
pneumococci
fq
still
level
rare
case
fqresist
h
influenza
report
h
influenza
catarrhali
remain
uniformli
sensit
fq
tabl
includ
result
doubl
blind
randomis
studi
ciprofloxacin
grepafloxacin
levofloxacin
gemifloxacin
gatifloxacin
moxifloxacin
compar
differ
macrolid
antibiot
azythromycin
clarithromycin
blactam
antibiot
amoxyclinclavulan
cefuroxim
axetil
treatment
acut
exacerb
cb
fq
except
ciprofloxacin
use
treatment
cours
day
treatment
cours
compar
antibiot
studi
includ
cb
patient
type
type
ii
acut
exacerb
determin
anthonisen
studi
criteria
clinic
respons
assess
day
treatment
deem
favour
case
none
studi
show
statist
signific
differ
treatment
arm
bacteri
elimin
rate
rang
four
studi
sputum
cultur
becom
neg
significantli
higher
percentag
patient
treat
fq
compar
antibiot
use
sever
studi
conduct
chodosh
wilson
time
interv
end
antibiot
treatment
next
acut
exacerb
episod
analys
demonstr
interv
free
diseas
significantli
longer
group
patient
treat
fq
besid
advantag
evid
result
includ
better
qualiti
life
patient
lower
cost
ill
reduct
number
acut
exacerb
episod
impli
better
preserv
antibiot
suscept
due
lesser
usag
also
slow
rate
damag
patient
respiratori
function
sever
studi
link
annual
number
acut
exacerb
overal
data
gather
clinic
effect
studi
use
differ
fq
antibiot
suggest
intrins
differ
activ
differ
antibacteri
spectrum
activ
differ
abil
penetr
bronchial
mucu
achiev
similar
clinic
cure
rate
provid
abl
reduc
bacteri
popul
densiti
threshold
inflammatori
respons
tend
remain
long
period
even
worsen
antibiot
achiev
greater
reduct
bacteri
load
acut
exacerb
abl
defer
longer
next
exacerb
episod
could
explain
fact
must
follow
exacerb
episod
start
lower
bacteri
load
count
probabl
improv
inflamm
relat
lower
bacteri
load
patient
persist
colonis
show
greater
degre
inflamm
throughout
period
clinic
stabil
among
possibl
secondari
untoward
effect
fq
use
particularli
relev
prescrib
patient
cb
develop
tendon
injuri
possibl
prolong
qt
interv
interact
drug
nearli
patient
fq
treatment
develop
arthralgia
infrequ
achil
tendon
injuri
includ
risk
tendon
ruptur
untoward
effect
like
develop
patient
chronic
renal
failur
patient
treat
steroid
drug
median
durat
fq
treatment
onset
tendon
injuri
day
prolong
qt
interv
main
factor
market
withdraw
sparfloxacin
grepafloxacin
healthi
volunt
mg
dose
levofloxacin
mg
dose
ciprofloxacin
induc
ms
prolong
qt
interv
studi
dose
mg
moxifloxacin
result
ms
qt
prolong
risk
cardiac
dysrhythmia
torsad
de
point
low
could
increas
patient
hypokaliemia
major
cardiac
diseas
take
sever
antiarrhythm
drug
amiodaron
quinidin
procainamid
sotalol
tricycl
antidepress
antipsychot
drug
treatment
also
lead
qt
prolong
hypotens
describ
use
garenoxacin
among
possibl
drugdrug
interact
low
probabl
develop
nonsolubl
compound
whenev
fq
administ
togeth
cation
calcium
iron
zinc
aluminum
reason
miner
dietari
supplement
antacid
compound
sucralf
significantli
reduc
fq
absorpt
antibiot
taken
least
h
h
ciprofloxacin
increas
plasma
level
theophyllin
inhibit
cytochrom
effect
levofloxacin
gatifloxacin
moxifloxacin
theophyllin
metabol
minim
gatifloxacin
interact
oral
hypoglycem
agent
induc
hypoglycemia
treatment
cb
acut
exacerb
fq
antibiot
achiev
clinic
cure
rate
least
similar
antibiot
group
blactam
macrolid
fq
addit
advantag
singl
daili
oral
dose
use
treatment
cours
usual
enough
greater
efficaci
fq
antibiot
reduc
bacteri
load
well
like
implic
effect
durat
interv
free
exacerb
togeth
slow
rate
function
impair
justifi
consider
fq
firstchoic
antibiot
treatment
notabl
patient
moder
sever
cb
fev
age
year
comorbid
condit
diabet
cardiac
diseas
cirrhosi
liver
chronic
renal
failur
patient
mild
cb
fev
age
year
without
comorbid
fq
antibiot
option
treatment
amoxycillinclavulan
telithromycin
use
area
high
resist
rate
macrolid
among
pneumococci
prudent
state
clearli
differ
order
avoid
widespread
use
fq
cb
acut
exacerb
episod
warrant
treatment
reduc
likelihood
resist
develop
cb
patient
prior
histori
four
acut
exacerb
episod
requir
antibiot
treatment
period
high
risk
p
aeruginosa
colonis
case
recommend
sputum
sampl
cultur
antibiot
suscept
test
alway
obtain
p
aeruginosa
resist
rate
fq
area
high
result
becom
avail
oral
antibiot
treatment
consid
ciprofloxacin
levofloxacin
use
